$17.76
4.44% yesterday
Nasdaq, May 20, 09:48 pm CET
ISIN
US6412881053
Symbol
NPCE

NeuroPace Inc Stock price

$17.99
+7.45 70.68% 1M
+8.80 95.76% 6M
+6.80 60.77% YTD
+10.01 125.44% 1Y
+11.94 197.36% 3Y
+0.99 5.82% 5Y
+0.99 5.82% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.99 5.82%
ISIN
US6412881053
Symbol
NPCE
Sector

Key metrics

Market capitalization $590.05m
Enterprise Value $596.94m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 7.08
P/S ratio (TTM) P/S ratio 7.00
P/B ratio (TTM) P/B ratio 24.28
Revenue growth (TTM) Revenue growth 22.05%
Revenue (TTM) Revenue $84.31m
EBIT (operating result TTM) EBIT $-19.27m
Free Cash Flow (TTM) Free Cash Flow $-18.14m
Cash position $66.26m
EPS (TTM) EPS $-0.83
P/E forward negative
P/S forward 6.22
EV/Sales forward 6.30
Short interest 2.04%
Show more

Is NeuroPace Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

NeuroPace Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a NeuroPace Inc forecast:

7x Buy
100%

Analyst Opinions

7 Analysts have issued a NeuroPace Inc forecast:

Buy
100%

Financial data from NeuroPace Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
84 84
22% 22%
100%
- Direct Costs 21 21
18% 18%
25%
63 63
23% 23%
75%
- Selling and Administrative Expenses 53 53
4% 4%
62%
- Research and Development Expense 25 25
19% 19%
30%
-15 -15
40% 40%
-18%
- Depreciation and Amortization 4.44 4.44
172% 172%
5%
EBIT (Operating Income) EBIT -19 -19
27% 27%
-23%
Net Profit -25 -25
21% 21%
-29%

In millions USD.

Don't miss a Thing! We will send you all news about NeuroPace Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

NeuroPace Inc Stock News

Neutral
Seeking Alpha
7 days ago
NeuroPace, Inc. (NASDAQ:NPCE ) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants Jeremy Feffer - LifeSci Advisors Joel Becker - Chief Executive Officer Rebecca Kuhn - Chief Financial Officer Conference Call Participants Mike Kratky - Leerink Partners Nelson Cox - Lake Street Ross Osborn - Cantor Fitzgerald Priya Sachdev - UBS Rohin Patel - JPMorgan Michael Polark - W...
Neutral
GlobeNewsWire
7 days ago
-- Reported record quarterly revenue of $22.5 million in Q1 2025, driven by increasing market demand for core RNS System products -- -- Increased full-year 2025 revenue guidance to $93 to $97 million -- -- On track to announce topline data from the NAUTILUS pivotal study in the second half of 2025 -- -- Management scheduled to host a conference call today at 4:30 p.m. ET -- MOUNTAIN VIEW, Calif.
Neutral
GlobeNewsWire
about one month ago
-- Minimal expected impact to operations and financial results -- -- Company to report first quarter 2025 financial results on May 13, 2025 --
More NeuroPace Inc News

Company Profile

NeuroPace, Inc. develops, manufactures and markets implantable devices for treating epilepsy and neurological disorders. It offers implantable components which include the RNS neurostimulator as well as depth and cortical strip leads. The firm's product RNS system is designed for the treatment of medically refractory partial epilepsy includes implantable and external products. The company was founded by Robert Fischell, David Fischell, Tim Fischell, Scott Fischell, Rebecca L. Kuhn, Frank M. Fischer and Martha Morrell on November 19, 1997 and is headquartered in Mountain View, CA.

Head office United States
CEO Joel Becker
Employees 184
Founded 1997
Website www.neuropace.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today